Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Cash from Investing Activities (2016 - 2022)

Edesa Biotech's Cash from Investing Activities history spans 10 years, with the latest figure at $41.0 for Q3 2022.

  • For Q3 2022, Cash from Investing Activities fell 97.2% year-over-year to $41.0; the TTM value through Sep 2022 reached -$5656.0, up 7.97%, while the annual FY2022 figure was -$5656.0, 7.97% up from the prior year.
  • Cash from Investing Activities for Q3 2022 was $41.0 at Edesa Biotech, up from -$1358.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $6.4 million in Q2 2019 and bottomed at -$635887.0 in Q3 2018.
  • The 5-year median for Cash from Investing Activities is -$1199.0 (2022), against an average of $408291.8.
  • The largest annual shift saw Cash from Investing Activities skyrocketed 93348.03% in 2019 before it tumbled 176.65% in 2021.
  • A 5-year view of Cash from Investing Activities shows it stood at -$635887.0 in 2018, then increased by 24.94% to -$477293.0 in 2019, then skyrocketed by 99.76% to -$1135.0 in 2020, then tumbled by 176.65% to -$3140.0 in 2021, then skyrocketed by 101.31% to $41.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Cash from Investing Activities are $41.0 (Q3 2022), -$1358.0 (Q2 2022), and -$1199.0 (Q1 2022).